Novo Nordisk’s Oral GLP-1 Offensive Meets a Wall Street Reality Check
Novo Nordisk faces revenue squeeze as oral Wegovy prescriptions plateau at starter doses, Eli Lilly enters the pill-based…
Generic Competition Meets a Pipeline Showcase
Novo Nordisk enters a critical period with Q1 earnings due May 6, a Canadian Ozempic generic launch, stock…
Teen Pill Success Meets Canadian Generic Shock
Novo Nordisk celebrates positive trial results for oral semaglutide in teens while facing first generic Ozempic competition in…
Novo Nordisk Faces a Fork in the Road as Pipeline Progress Meets Profit Pressure
Novo Nordisk stock trades 50% below peak amid GLP-1 competition from Eli Lilly’s oral pill, regulatory wins, and…
Novo Nordisk’s Subscription Gamble Meets a Formidable New Rival
Novo Nordisk shares fall 50% from highs as Eli Lilly’s oral GLP-1 pill challenges Wegovy. The firm launches…
Alphabet’s $185 Billion Bet Meets Brussels’ Wrath
Alphabet faces EU antitrust action over search data while investing up to $185B in AI infrastructure. Q1 earnings…
Novo Nordisk’s AI Drive Meets a Harsh Pricing Reality
Novo Nordisk shares fall 50% from highs on 2026 profit warning, US market loss to Eli Lilly, and…
Novo Nordisk’s AI Gambit Meets a Brutal Price War
Novo Nordisk partners with OpenAI to counter Eli Lilly’s tech edge while slashing prices in a fierce weight-loss…
Novo Nordisk’s European Logistics Breakthrough Meets US Pricing Headwinds
EMA relaxes Wegovy cold-chain rules, cutting EU distribution costs. Novo faces 2026 sales decline from US pricing pressure…